Current Report Filing (8-k)
January 04 2021 - 7:56AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 4, 2021
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
000-54986
|
|
46-0524102
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
235 Walnut Street, Suite 6
|
|
|
Framingham, Massachusetts
|
|
01702
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (617) 431-2313
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
N|A
|
N|A
|
N|A
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01
|
Regulation FD Disclosure.
|
On January 4, 2021, Arch Therapeutics, Inc. (the “Company”)
issued a press release announcing its entrance into a distribution and sales administration agreement with Buffalo Supply, Inc.
(“BSI”), pursuant to which BSI will serve as the Company’s exclusive distributor for products sold to
United States government facilities worldwide.
The text of the press release is attached hereto as Exhibit
99.1 and is incorporated by reference herein.
The disclosure under Item 7.01 (Regulation FD Disclosure) is
incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits
|
(d)
The following exhibits are being filed herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARCH THERAPEUTICS, INC.
|
|
|
Dated: January 4, 2021
|
By:
|
/s/ Terrence W. Norchi, M.D.
|
|
Name:
|
Terrence W. Norchi, M.D.
|
|
Title:
|
President, Chief Executive Officer
|
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Sep 2023 to Sep 2024